Omega Therapeutics, Inc.

OMGA

US68217N1054

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:20:24 2024-04-16 am EDT			5-day change	1st Jan Change
2.435 ^USD	-3.18%		-20.20%	-19.93%

Apr. 09	Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	CI
Mar. 28	Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	MT

Omega Therapeutics, Inc.(NasdaqGS:OMGA) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Omega Therapeutics, Inc.

Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	Apr. 09	CI
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	Mar. 28	MT
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management	Jan. 05	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 04	MT
Top Midday Gainers	Jan. 04	MT
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research	Jan. 04	MT
Top Premarket Gainers	Jan. 04	MT
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms	Jan. 04	RE
Novo Nordisk Signs Research Deals With Omega Therapeutics, Cellarity	Jan. 04	MT
Novo Nordisk: research agreements with Omega and Cellarity	Jan. 04	CF
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms	Jan. 04	RE
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis	Nov. 13	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC	23-10-16	CI
Omega Therapeutics Study of OTX-2002 Shows High Engagement With Patients, Without Dose-Limiting Toxicities	23-09-26	MT
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial	23-09-26	CI
Omega Therapeutics, Inc.(NasdaqGS:OMGA) added to S&P Global BMI Index	23-09-18	CI
Omega Therapeutics, Inc. Announces Board Changes	23-08-29	CI
Omega Therapeutics, Inc. Appoints Chris Schade as Chairman of the Board	23-08-29	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

Chart Omega Therapeutics, Inc.

Duration

Period

More charts

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Companyâs OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Companyâs precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Omega Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.515 USD

Average target price

11 USD

Spread / Average Target

+337.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OMEGA THERAPEUTICS, INC.	-19.93%	139M
LONZA GROUP AG	+48.54%	42.16B
IQVIA HOLDINGS INC.	-0.55%	42.07B
MODERNA, INC.	+5.78%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+4.31%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-23.15%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.29%	12.11B
MEDPACE HOLDINGS, INC.	+26.66%	11.99B
UNITED THERAPEUTICS CORPORATION	+5.18%	11.06B

Other Biotechnology & Medical Research